Drug Trial Radar · NCT06954584
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
424
Planned (sponsor's estimate)
Start
May 27, 2025
Primary completion
May 1, 2030
Study completion Mar 1, 2032
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP inhibitors . In vitro evidence suggests that low-carbohydrate culture conditions may restore PARP inhibitor sensitivity in HRD-negative tumor cells. This study aims to validate the survival benefits of fluzoparib combined with bevacizumab in HRD-positive ovarian cancer patients during first-line maintenance therapy and explore the efficacy of fluzoparib combined with a dietary intervention in HRD-negative populations.
Conditions
- Ovarian Cancer
Interventions
BevacizumabDrug
Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 15 months
Fluzoparib MonotherapyDrug
150 mg orally bid (50 mg/capsule, 3 capsules/dose)
Dietary InterventionBehavioral
Control carbohydrate intake in the daily diet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.